Prelude Therapeutics Appoints Paul Scherer as Director

Prelude Therapeutics ( (PRLD) ) just unveiled an update.

On June 11, 2025, Prelude Therapeutics appointed Paul Scherer, M.D., as a Class III director and member of the Compensation and Governance Committees, effective after the 2025 Annual Meeting of Stockholders on June 12, 2025. Dr. Scherer, with a background in neuroscience and experience advising biotech firms, will serve until the 2026 Annual Meeting. During the Annual Meeting, the election of two Class II Directors, Martin Babler and Victor Sandor, was confirmed, and Ernst & Young LLP was ratified as the independent auditor for 2025. Additionally, an amendment to increase the number of authorized shares of non-voting common stock was approved.

The most recent analyst rating on (PRLD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.

Spark’s Take on PRLD Stock

According to Spark, TipRanks’ AI Analyst, PRLD is a Underperform.

Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.

To see Spark’s full report on PRLD stock, click here.

More about Prelude Therapeutics

Prelude Therapeutics is a biotechnology company focused on developing innovative therapies for cancer treatment. The company operates in the biopharmaceutical industry, aiming to address unmet medical needs through its research and development efforts.

Average Trading Volume: 185,255

Technical Sentiment Signal: Sell

Current Market Cap: $61.82M

For a thorough assessment of PRLD stock, go to TipRanks’ Stock Analysis page.